keyword
MENU ▼
Read by QxMD icon Read
search

non-alcoholic steatohepatitis AND (treatment or therapy)

keyword
https://www.readbyqxmd.com/read/28533225/multi-functional-effects-of-a-small-molecule-stat3-inhibitor-on-nash-and-hcc-in-mice
#1
Kwang Hwa Jung, Wonbeak Yoo, Heather L Stevenson, Dipti Deshpande, Hong Shen, Mihai Gagea, Suk-Young Yoo, Jing Wang, Thomas Kris Eckols, Uddalak Bharadwaj, David J Tweardy, Laura Beretta
The incidence of hepatocellular carcinoma (HCC) is increasing in the United States and liver cancer is the second leading cause of cancer-related mortality worldwide. Non-alcoholic steatohepatitis (NASH) is becoming an important risk for HCC and most patients with HCC have underlying liver cirrhosis and compromised liver function, which limit treatment options. Thus, novel therapeutic strategies to prevent or treat HCC in the context of NASH and cirrhosis are urgently needed. <br /><br />Experimental Design: Constitutive activation of signal transducer and activator of transcription 3 (STAT3) is frequently detected in HCC tumors...
May 22, 2017: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/28525362/fgf21-receptor-agonists-an-emerging-therapeutic-class-for-obesity-related-diseases
#2
Junichiro Sonoda, Mark Z Chen, Amos Baruch
Fibroblast growth factor 21 (FGF21) analogs and FGF21 receptor agonists (FGF21RAs) that mimic FGF21 ligand activity constitute the new "FGF21-class" of anti-obesity and anti-diabetic molecules that improve insulin sensitivity, ameliorate hepatosteatosis and promote weight loss. The metabolic actions of FGF21-class proteins in obese mice are attributed to stimulation of brown fat thermogenesis and increased secretion of adiponectin. The therapeutic utility of this class of molecules is being actively investigated in clinical trials for the treatment of type 2 diabetes and non-alcoholic steatohepatitis (NASH)...
May 19, 2017: Hormone Molecular Biology and Clinical Investigation
https://www.readbyqxmd.com/read/28521870/the-use-of-statins-alone-or-in-combination-with-pioglitazone-and-other-drugs-for-the-treatment-of-non-alcoholic-fatty-liver-disease-non-alcoholic-steatohepatitis-and-related-cardiovascular-risk-an-expert-panel-statement
#3
REVIEW
Vasilios G Athyros, Theodore K Alexandrides, Helen Bilianou, Evangelos Cholongitas, Michael Doumas, Emmanuel S Ganotakis, John Goudevenos, Moses S Elisaf, Georgios Germanidis, Olga Giouleme, Asterios Karagiannis, Charalambos Karvounis, Niki Katsiki, Vasilios Kotsis, Jannis Kountouras, Evangelos Liberopoulos, Christos Pitsavos, Stergios Polyzos, Loukianos S Rallidis, Dimitrios Richter, Apostolos G Tsapas, Alexandros D Tselepis, Konstantinos Tsioufis, Konstantinos Tziomalos, Themistoklis Tzotzas, Themistoklis G Vasiliadis, Charalambos Vlachopoulos, Dimitri P Mikhailidis, Christos Mantzoros
Non-alcoholic fatty liver disease (NAFLD), the most common liver disease, is characterized by accumulation of fat (>5% of the liver tissue), in the absence of alcohol abuse or other chronic liver diseases. It is closely related to the epidemic of obesity, metabolic syndrome or type 2 diabetes mellitus (T2DM). NAFLD can cause liver inflammation and progress to non-alcoholic steatohepatitis (NASH), fibrosis, cirrhosis or hepatocellular cancer (HCC). Nevertheless, cardiovascular disease (CVD) is the most common cause of death in NAFLD/NASH patients...
June 2017: Metabolism: Clinical and Experimental
https://www.readbyqxmd.com/read/28517024/treatment-of-severe-alcoholic-hepatitis-past-present-and-future
#4
REVIEW
Nicolas Lanthier, Peter Stärkel
Alcoholic hepatitis manifests as a clinical syndrome characterized by recent jaundice and liver function deterioration in an actively drinking patient. The principal cause of alcoholic hepatitis is alcoholic steatohepatitis defined histologically by the coexistence of steatosis, hepatocyte ballooning and satellitosis. While non-severe alcoholic hepatitis usually responds to alcohol abstinence, severe alcoholic hepatitis, identified by Maddrey scoring ≥ 32, has a bad prognosis and is traditionally treated by a 28-day course of prednisone therapy...
May 18, 2017: European Journal of Clinical Investigation
https://www.readbyqxmd.com/read/28511161/-the-diagnostics-and-clinical-pattern-of-nonalcoholic-fatty-liver-disease-in-patients-with-pre-diabetes-and-type-2-diabetes-and-obesity
#5
Ксенія І Чубірко
INTRODUCTION: The data of epidemiological researches confirm the tendency in increasing of non alcoholic fatty liver disease (NAFLD) in patients with insulin resistance which occurs because of obesity, diabetes type 2 and metabolic syndrome. AIM: Optimization of diagnostic and treatment efficacy in patients with non alcoholic steatosis and steatohepatitis on the background of obesity. MATERIALS AND METHODS: General clinical examination of patients, laboratory and instrumental methods ( fatty liver index, non invasive assessment of liver, morphology, electrocardiography, treadmillergometry, ultrasound examination of abdominal organs, liver elastography,CT,MRI, methods of statistical analysis...
2017: Wiadomości Lekarskie: Organ Polskiego Towarzystwa Lekarskiego
https://www.readbyqxmd.com/read/28511023/efficacy-of-docosahexaenoic-acid-choline-vitamin-e-dha-cho-ve-in-paediatric-nash-a-randomized-controlled-clinical-trial
#6
Evelyn Zöhrer, Alisi Anna, Jörg Jahnel, Antonella Moscla, Claudia Della Corte, Annalisa Crudele, Günter Fauler, Valerio Nobili
Non-alcoholic steatohepatitis (NASH), a progressive form of non-alcoholic fatty liver disease (NAFLD), is one of the most common hepatic diseases in children. We conducted a randomized controlled clinical trial on children with biopsy-proven NASH based on a combinatorial nutritional approach compared to placebo. Participants were assigned to lifestyle modification plus placebo, or lifestyle modification plus a mix containing docosahexaenoic acid, choline and vitamin E (DHA-CHO-VE). Forty children and adolescents concluded the trial...
May 16, 2017: Applied Physiology, Nutrition, and Metabolism, Physiologie Appliquée, Nutrition et Métabolisme
https://www.readbyqxmd.com/read/28498022/thyroid-hormone-analogs-for-the-treatment-of-dyslipidemia-past-present-and-future
#7
Alessandro P Delitala, Giuseppe Delitala, Paolo Sioni, Giuseppe Fanciulli
OBJECTIVE: Treatment of dyslipidemia is a major burden for public health. Thyroid hormone regulates lipid metabolism by binding the thyroid hormone receptor (TR), but the use of thyroid hormone to treat dyslipidemia is not indicated due to its deleterious effects on heart, bone, and muscle. Thyroid hormone analogs have been conceived to selectively activate TR in the liver, thus reducing potential side effects. METHODS: We searched the PubMed database to review TR and the action of thyromimetics in vitro and in animal models...
May 12, 2017: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/28494529/nash-therapy-omega-3-supplementation-vitamin-e-insulin-sensitizers-and-statin-drugs
#8
Stephen Caldwell
Non-alcoholic steatohepatitis (NASH) is the more aggressive form of non-alcoholic fatty liver disease (NAFLD). NASH can progress to hepatic fibrosis, cirrhosis, portal hypertension and primary liver cancer. Therapy is evolving with a substantial number of trials of promising new agents now in progress. In this article however, we will examine data for several older forms of therapy which have been fairly extensively studied over the years: Polyunsaturated Fatty Acid (PUFA) supplements, vitamin E, insulin sensitizing agents with a focus on pioglitazone and statin agents...
May 10, 2017: Clinical and Molecular Hepatology
https://www.readbyqxmd.com/read/28484247/total-fecal-microbiota-transplantation-alleviates-high-fat-diet-induced-steatohepatitis-in-mice-via-beneficial-regulation-of-gut-microbiota
#9
Da Zhou, Qin Pan, Feng Shen, Hai-Xia Cao, Wen-Jin Ding, Yuan-Wen Chen, Jian-Gao Fan
Non-alcoholic steatohepatitis (NASH) is an epidemic metabolic disease with limited therapeutic strategies. Cumulative data support the pivotal role of gut microbiota in NASH. Here, we investigated the hypothesis regarding whether fecal microbiota transplantation (FMT) is effective in attenuating high-fat diet (HFD)-induced steatohepatitis in mice. Mice were randomized into control, HFD and HFD + FMT groups. After an 8-week HFD, FMT treatment was initiated and carried out for 8 weeks. The gut microbiota structure, butyrate concentrations of the cecal content, liver pathology and intrahepatic lipid and cytokines were examined...
May 8, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28481357/tmbim1-is-a-multivesicular-body-regulator-that-protects-against-non-alcoholic-fatty-liver-disease-in-mice-and-monkeys-by-targeting-the-lysosomal-degradation-of-tlr4
#10
Guang-Nian Zhao, Peng Zhang, Jun Gong, Xiao-Jing Zhang, Pi-Xiao Wang, Miao Yin, Zhou Jiang, Li-Jun Shen, Yan-Xiao Ji, Jingjing Tong, Yutao Wang, Qiao-Fang Wei, Yong Wang, Xue-Yong Zhu, Xin Zhang, Jing Fang, Qingguo Xie, Zhi-Gang She, Zhihua Wang, Zan Huang, Hongliang Li
Non-alcoholic steatohepatitis (NASH) is an increasingly prevalent liver pathology that can progress from non-alcoholic fatty liver disease (NAFLD), and it is a leading cause of cirrhosis and hepatocellular carcinoma. There is currently no pharmacological therapy for NASH. Defective lysosome-mediated protein degradation is a key process that underlies steatohepatitis and a well-recognized drug target in a variety of diseases; however, whether it can serve as a therapeutic target for NAFLD and NASH remains unknown...
May 8, 2017: Nature Medicine
https://www.readbyqxmd.com/read/28467181/pre-clinical-and-clinical-investigations-of-metabolic-zonation-in-liver-diseases-the-potential-of-microphysiology-systems
#11
Alejandro Soto-Gutierrez, Albert Gough, Lawrence A Vernetti, D L Taylor, Satdarshan P Monga
The establishment of metabolic zonation within a hepatic lobule ascribes specific functions to hepatocytes based on unique, location-dependent gene expression patterns. Recently, there have been significant developments in the field of metabolic liver zonation. A little over a decade ago, the role of β-catenin signaling was identified as a key regulator of gene expression and function in pericentral hepatocytes. Since then, additional molecules have been identified that regulate the pattern of Wnt/β-catenin signaling within a lobule and determine gene expression and function in other hepatic zones...
January 1, 2017: Experimental Biology and Medicine
https://www.readbyqxmd.com/read/28464257/significant-positive-association-of-endotoxemia-with-histological-severity-in-237-patients-with-non-alcoholic-fatty-liver-disease
#12
J Pang, W Xu, X Zhang, G L-H Wong, A W-H Chan, H-Y Chan, C-H Tse, S S-T Shu, P C-L Choi, H L-Y Chan, J Yu, V W-S Wong
BACKGROUND: Patients with nonalcoholic steatohepatitis (NASH) have gut dysbiosis and intestinal bacterial overgrowth. AIM: To test the hypothesis that endotoxemia is associated with the histological severity of nonalcoholic fatty liver disease (NAFLD) and determine factors associated with endotoxemia. METHODS: The endotoxemia markers lipopolysaccharide-binding protein (LBP) and endotoxin levels were measured in 237 NAFLD patients 1 day before liver biopsy...
May 2, 2017: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/28457061/association-between-fatty-liver-disease-and-hyperplastic-colonic-polyp
#13
Mahmud Mahamid, Tarik Yassin, Omar Abu Elheja, William Nseir
BACKGROUND: Hyperplastic polyps (HPs) of the colon are the most common colorectal polyps. Metabolic syndrome components such as obesity and hyperlipidemia are considered the most common etiological factors for HPs as well contributing to the pathogenesis of fatty liver disease. OBJECTIVES: To determine the possible association between biopsy-proven steatohepatitis and hyperplastic colonic polyps. METHODS: This retrospective cohort observational study conducted at the Holy Family Hospital in Nazareth, Israel, included subjects who underwent screening colonoscopy over a 2 year period...
February 2017: Israel Medical Association Journal: IMAJ
https://www.readbyqxmd.com/read/28454924/dual-effect-of-silymarin-on-experimental-non-alcoholic-steatohepatitis-induced-by-irinotecan
#14
Eudmar Marcolino Assis-Júnior, Anielle Torres Melo, Venúcia Bruna Magalhães Pereira, Deysi Viviana Tenazoa Wong, Nathalia Ribeiro Pinho Sousa, Christiane Mendes Gonçalves Oliveira, Lara Raissa Cavalcante Malveira, Leonardo Silva Moreira, Marcellus Henrique Loiola Ponte Souza, Paulo Roberto Carvalho Almeida, Roberto César Pereira Lima-Júnior
Irinotecan-based regimens are commonly used for treatment of colorectal cancer, which is limited by mucositis and non-alcoholic steatohepatitis (NASH). Silymarin (SIL) prevents fatty liver disease in the clinical setting and in models of liver damage induced chemically. This study investigated the possible effect of SIL on irinotecan (IRI)-induced NASH. Swiss female mice were injected with saline (SAL 5ml/kg i.p.), IRI (50mg/kg i.p.), SIL (150mg/kg p.o.) or IRI (50mg/kg i.p.)+(SIL 1.5, 15 or 150mg/kg p.o.) thrice/week/7weeks...
April 26, 2017: Toxicology and Applied Pharmacology
https://www.readbyqxmd.com/read/28452727/-the-influence-of-lifestyle-on-biomarkers-of-fibrosis-in-patients-with-stable-coronary-heart-disease-on-the-background-of-non-alcoholic-fatty-liver-disease
#15
N Virstyuk, I Vakalyuk
Purpose - to assess the impact of lifestyle on non-alcoholic fatty liver disease (NAFLD) activity by influencing the fibrotic processes and hepatic steatosis in patients with stable coronary heart disease (CHD). 105 patients with stable CHD, combined with NAFLD were observed: Group I - control group; Group II - basic group. In each group, patients with non-alcoholic steatosis (subgroup A) and non-alcoholic steatohepatitis (subgroup B) were isolated. General clinical examination, electrocardiography, coronary angiography, echocardiography, liver functional state, serum lipid profile, fasting glucose, markers of fibrosis were conducted to all patients...
February 2017: Georgian Medical News
https://www.readbyqxmd.com/read/28446519/cationic-polystyrene-resolves-nonalcoholic-steatohepatitis-nash-obesity-and-metabolic-disorders-by-promoting-eubiosis-of-gut-microbiota-and-decreasing-endotoxemia
#16
Airu Zhu, Jingjing Chen, Pengfei Wu, Mei Luo, Yilan Zeng, Han Zheng, Li Zhang, Zishou Cheng, Qun Sun, Wenwen Li, Yixiang Duan, Danmei Su, Zhixiong Xiao, Zhongping Duan, Sujun Zheng, Li Bei, Xiaohui Zhang, Zhongyuan Ju, Richard Hu, Stephen J Pandol, Yuan-Ping Han
A pandemic of metabolic diseases, consisting of type-2 diabetes, non-alcoholic fatty liver diseases (NAFLD) and obesity, has imposed critical challenges for societies worldwide, prompting investigation of underlying mechanisms and exploration of low cost and effective treatment. In this report, we demonstrate that metabolic disorders in mice generated by feeding with a high-fat diet without dietary vitamin D (HD) can be prevented by oral administration of polycationic amine resin. Oral administration of cholestyramine , but not the control uncharged polystyrene, was able to sequester negatively charged bacterial endotoxin in the gut, leading to (1) reducing plasma endotoxin levels, (2) resolving systemic inflammation and hepatic steatohepatitis,and (3) improving insulin sensitivity...
April 26, 2017: Diabetes
https://www.readbyqxmd.com/read/28437865/a-novel-role-of-astrocyte-elevated-gene-1-aeg-1-in-regulating-non-alcoholic-steatohepatitis-nash
#17
Jyoti Srivastava, Chadia L Robertson, Kareem Ebeid, Mikhail Dozmorov, Devaraja Rajasekaran, Rachel Mendoza, Ayesha Siddiq, Maaged A Akiel, Nidhi Jariwala, Xue-Ning Shen, Jolene J Windle, Mark A Subler, Nitai D Mukhopadhyay, Shah Giashuddin, Shobha Ghosh, Zhao Lai, Yidong Chen, Paul B Fisher, Aliasger K Salem, Arun J Sanyal, Devanand Sarkar
Nonalcoholic steatohepatitis (NASH) is the most prevalent cause of chronic liver disease in the Western world. However, an optimum therapy for NASH is yet to be established mandating more in-depth investigation into the molecular pathogenesis of NASH to identify novel regulatory molecules and develop targeted therapies. Here, we unravel a unique function of Astrocyte elevated gene-1/Metadherin (AEG-1/MTDH) in NASH using a transgenic mouse with hepatocyte-specific overexpression of AEG-1 (Alb/AEG-1) and a conditional hepatocyte-specific AEG-1 knockout mouse (AEG-1(ΔHEP) )...
April 24, 2017: Hepatology: Official Journal of the American Association for the Study of Liver Diseases
https://www.readbyqxmd.com/read/28428116/cycloastragenol-improves-hepatic-steatosis-by-activating-farnesoid-x-receptor-signalling
#18
Ming Gu, Shiying Zhang, Yuanyuan Zhao, Jinwen Huang, Yahui Wang, Yin Li, Shengjie Fan, Li Yang, Guang Ji, Qingchun Tong, Cheng Huang
Non-alcoholic fatty liver disease (NAFLD) has become a global health problem. However, there is no approved therapy for NAFLD. Farnesoid X receptor (FXR) is a potential drug target for treatment of NAFLD. In an attempt to screen FXR agonists, we found that cycloastragenol (CAG), a natural occurring compound in Astragali Radix, stimulated FXR transcription activity. In animal studies, we demonstrated that CAG treatment resulted in obvious reduction of high-fat diet induced lipid accumulation in liver accompanied by lowered blood glucose, serum triglyceride levels and hepatic bile acid pool size...
April 18, 2017: Pharmacological Research: the Official Journal of the Italian Pharmacological Society
https://www.readbyqxmd.com/read/28425154/rifaximin-in-non-alcoholic-steatohepatitis-an-open-label-pilot-study
#19
Jeremy F L Cobbold, Stephen Atkinson, Julian R Marchesi, Ann Smith, Sann N Wai, Julie Stove, Fariba Shojaee-Moradie, Nicola Jackson, A Margot Umpleby, Julie Fitzpatrick, E Louise Thomas, Jimmy D Bell, Elaine Holmes, Simon D Taylor-Robinson, Robert D Goldin, Michael S Yee, Quentin M Anstee, Mark R Thursz
AIM: Gut microbial dysbiosis is implicated in the pathogenesis of non-alcoholic steatohepatitis (NASH). We investigated downstream effects of gut microbiota modulation on markers of hepatic inflammation, steatosis, and hepatic and peripheral insulin sensitivity in patients with NASH using Rifaximin therapy. METHODS: Patients with biopsy-proven NASH and elevated aminotransferase values were included in this open-label pilot study, all receiving 6 weeks Rifaximin 400 mg twice daily, followed by a 6 week observation period...
April 20, 2017: Hepatology Research: the Official Journal of the Japan Society of Hepatology
https://www.readbyqxmd.com/read/28420094/nonalcoholic-fatty-liver-disease-and-insulin-resistance-new-insights-and-potential-new-treatments
#20
REVIEW
Hironori Kitade, Guanliang Chen, Yinhua Ni, Tsuguhito Ota
Nonalcoholic fatty liver disease (NAFLD) is one of the most common chronic liver disorders worldwide. It is associated with clinical states such as obesity, insulin resistance, and type 2 diabetes, and covers a wide range of liver changes, ranging from simple steatosis to non-alcoholic steatohepatitis (NASH), liver cirrhosis, and hepatocellular carcinoma. Metabolic disorders, such as lipid accumulation, insulin resistance, and inflammation, have been implicated in the pathogenesis of NAFLD, but the underlying mechanisms, including those that drive disease progression, are not fully understood...
April 14, 2017: Nutrients
keyword
keyword
82832
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"